Dr. Todd Morgan

Todd M. Morgan, M.D. is a urological surgeon and Chief of Urologic Oncology at Michigan Medicine. Dr. Morgan is originally from Seattle, WA and completed his undergraduate and medical training at Harvard University. He returned to the Northwest in 2003 for his urology residency at the University of Washington, before moving to Nashville for his fellowship training in urological oncology at Vanderbilt University. In addition to being a clinician and surgeon, Dr. Morgan is a translational surgeon-scientist. His research involves developing blood-based tests that can guide precision-based treatments for prostate cancer in real time, and he is principal investigator of two large randomized controlled trials evaluating tissue-based biomarkers in men with localized prostate cancer. Dr. Morgan has been the recipient of Young Investigator Awards from the Prostate Cancer Foundation, Society for Urological Oncology, National Comprehensive Cancer Network (NCCN), and Society for Basic Urology Research. He has served on a number of national guideline committees, such as the AUA Muscle-Invasive Bladder Cancer Guidelines, the AUA Advanced Prostate Cancer Guidelines, the NCCN Prostate Cancer Early Detection Guidelines, The ASCO Localized Prostate Cancer Guidelines, and the ASCO Molecular Markers for Prostate Cancer Guidelines.

Most importantly, Dr. Morgan is dedicated to caring for patients with genitourinary cancers. His urologic oncology practice includes caring for patients with prostate, bladder, kidney, and penile cancers, and his surgical expertise encompasses a wide spectrum of open, laparoscopic, and advanced robotic surgical approaches. He has substantial expertise in cancer genetics and the use and interpretation of molecular biomarkers, which can help guide individualized treatment choice for some patients.